[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"childhood-non-hodgkin-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:childhood-non-hodgkin-lymphoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100555183","long-term-follow-up-of-patients-treated-with-miltenyi-cell-and-gene-therapies-100555183",false,"NCT06508775","Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies","LONGSAFE","Inclusion Criteria:\n\n* Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.\n* Patient has provided informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* No exclusion criteria","ALL",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.",[25,26,27,28,29,30,31],"Melanoma Stage III","B-cell Non Hodgkin Lymphoma","Pediatric ALL","Childhood Non-Hodgkin Lymphoma","Acute Lymphatic Leukemia","Chronic Lymphatic Leukemia","Melanoma Stage IV","RECRUITING","2025-11-20",{"date":35,"type":36},"2025-11-26","ACTUAL",{"date":38,"type":36},"2024-05-05",{"date":40,"type":19},"2040-12-31",{"name":42,"class":43},"Miltenyi Biomedicine GmbH","INDUSTRY",7]